Menu
Aimed at minimizing or removing oral leukoplakia lesions.
Reducing the risk of patients developing oral cancer from it.
Oral leukoplakia is a potentially cancerous white patch or plaque in the mouth, strongly linked to smoking. The edges of the lesion are typically abrupt and the lesion changes. Oral leukoplakia also has dysplasia which highlights the severity of the disorder and is a marker of disease progression. Dysplasia is abnormal cell growth, a precancerous condition more serious than normal cell overgrowth (hyperplasia). In adults, precancerous dysplasia may not always turn into cancer, but there's a risk it could.
Bio-Converts mission is to develop the preferred treatment for oral leukoplakia. Our innovative therapeutic agent, QR-2, uses a novel drug delivery technology, that enables more precise, effective and efficient treatment.
Business Model
Enter into contracts with reputable partners possessing the appropriate technology to conduct clinical trials.
Formulation development.Conduct pre-clinical tests.
Submit global patent applications. Commence the initial clinical Proof of Concept (POC) study.
The anticipated timeline for advancing the development project is approx. 24 months, starting in November 2023.
Bio-Convert have identified a novel drug delivery technology, that we believe holds significant potential to become the preferred future treatment of oral leukoplakia (OL) using our unique patch, QR-2. The patch is applied directly to the lesions in the mouth. The treatment is intended to reduce/remove the OL lesions, and it will facilitate surgical procedure and improve, and reduce the malign conversion rate, lowering the risk of them turning into cancer.
Connect with us, and stay updated.
Receive our latest blog posts directly in your inbox!